MK-2921
Total Payments
$12,450
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $12,450 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,450 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1,2 Study of Derazantinib ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | Merck Sharp & Dohme Corporation | $12,450 | 0 |
Top Doctors Receiving Payments for MK-2921
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $12,450 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $12,450
Product Information
- Type Drug
- Total Payments $12,450
- Total Doctors 0
- Transactions 1
About MK-2921
MK-2921 is a drug associated with $12,450 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $12,450 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-2921 is "Unspecified" ($12,450, 100.0% of total).
MK-2921 is associated with 1 research study, including "Phase 1,2 Study of Derazantinib ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations" ($12,450).